The U.S. Food and Drug Administration requested that Emergent BioSolutions temporarily pause production of ingredients for the Johnson & Johnson Covid-19 vaccine at their facility in Baltimore.

The U.S. government will allot nearly 85 percent less Johnson & Johnson Covid-19 vaccines to states next week, data from Centers for Disease Control and Prevention (CDC) showed.

The United States put Johnson and Johnson in charge of a plant that ruined 15 million doses of the company’s Covid-19 vaccine and stopped British drugmaker AstraZeneca from using the facility, a senior health official said on April 3.

Johnson & Johnson’s manufacturing partner Emergent Biosolutions said on April 1 that the company disposed of the single batch of Covid-19 drug substance that did not meet specifications.

Johnson & Johnson said on March 31 the company had found a problem with a batch of the drug substance for its Covid-19 vaccine being produced by Emergent BioSolutions, and said the batch did not advance to the final fill-and-finish stage.